Prognostic Value of Stem Cell Related Markers

Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01265225

Enrollment

Registered

2010-12-23

Start date

2011-02-28

Completion date

2013-04-30

Last updated

2013-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer stages 0-II

Brief summary

The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Ductal Carcinoma in Situ * DCIS + Microinvasion stages 1 or 11 without positive lymph nodes

Exclusion criteria

* tumor specimen with higher than grade II * BRACA 1 or BRACA 2 mutation * Neoadjuvant chemotherapy

Countries

Israel

Outcome results